YuKyung Kim

2PUBLICATIONS
17CO-AUTHORS
Molecular targetsPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (2)

Sort by Publication Date:
|Jun 28, 2023
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With <i>EGFR</i>-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301.

Byoung Chul Cho, Myung-Ju Ahn, Jin Hyoung Kang

|Apr 25, 2023
Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl-tRNA synthetase inhibitor, in healthy subjects.

Min Young Park, Sungyeun Bae, Jung A Heo

Pageof 1

Frequent Collaborators

1 joint publications

Sungyeun Bae

1 joint publications

Kyung-Sang Yu

1 joint publications

Jaeseong Oh

1 joint publications

Byoung Chul Cho

1 joint publications

Myung-Ju Ahn

1 joint publications

Jin Hyoung Kang

1 joint publications

Ross A Soo

1 joint publications

James Chih-Hsin Yang

1 joint publications

Irfan Cicin

1 joint publications

Dong-Wan Kim

Frequent Collaborators

1 joint publications

Sungyeun Bae

1 joint publications

Kyung-Sang Yu

1 joint publications

Jaeseong Oh

1 joint publications

Byoung Chul Cho

JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

8.0K
A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against <i>S. pneumoniae</i>, <i>H. influenzae</i>, <i>K. pneumoniae</i>, <em>P. aeruginosa</em> or  <em>A. baumannii</em>
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against <i>S. pneumoniae</i>, <i>H. influenzae</i>, <i>K. pneumoniae</i>, <em>P. aeruginosa</em> or <em>A. baumannii</em>

Published on : Jan 02, 2017

14.8K
See more related videos

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

8.0K
A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against <i>S. pneumoniae</i>, <i>H. influenzae</i>, <i>K. pneumoniae</i>, <em>P. aeruginosa</em> or  <em>A. baumannii</em>
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against <i>S. pneumoniae</i>, <i>H. influenzae</i>, <i>K. pneumoniae</i>, <em>P. aeruginosa</em> or <em>A. baumannii</em>

Published on : Jan 02, 2017

14.8K
See more related videos